Answers are grounded in this paper and cite their sources.
This letter highlights an interpretative issue in a real-world landmark analysis of abrocitinib dose optimization in atopic dermatitis. Post-landmark dose re-escalations may complicate attribution of Week 24 disease control to Week 16 treatment trajectories, warranting clarification of subsequent treatment exposure and outcome timing.
No takes yet. Share an insight, caveat, or question.
Fatih Kaplan (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: